Group One Trading
URGN icon

Group One Trading’s UroGen Pharma URGN Stock Holding History

Group One Trading’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,000
Closed -$1.71M – 8813
2025
Q4 		$1.71M Sell
73,000
-42,400
-37% -$920K ﹤0.01% 2415
2025
Q3 		$2.3M Sell
115,400
-184,700
-62% -$3.32M ﹤0.01% 2172
2025
Q2 		$4.11M Buy
300,100
+243,800
+433% +$2.34M 0.01% 1477
2025
Q1 		$623K Buy
56,300
+51,600
+1,098% +$550K ﹤0.01% 2877
2024
Q4 		$50.1K Buy
4,700
+2,900
+161% +$34.7K ﹤0.01% 5053
2024
Q3 		$22.9K Sell
1,800
-16,700
-90% -$248K ﹤0.01% 5164
2024
Q2 		$310K Buy
18,500
+14,900
+414% +$212K ﹤0.01% 3007
2024
Q1 		$54K Buy
3,600
+3,500
+3,500% +$57.2K ﹤0.01% 4657
2023
Q4 		$1.5K Sell
100
-10,200
-99% -$132K ﹤0.01% 6899
2023
Q3 		$144K Buy
10,300
+4,600
+81% +$73.8K ﹤0.01% 4100
2023
Q2 		$59K Buy
5,700
+3,800
+200% +$41.9K ﹤0.01% 5131
2023
Q1 		$17.6K Buy
1,900
+1,400
+280% +$12.9K ﹤0.01% 5596
2022
Q4 		$4.43K Sell
500
-100
-17% -$947 ﹤0.01% 6390
2022
Q3 		$50K Buy
+600
New +$4.96K ﹤0.01% 5407
2021
Q4 		– Sell
-50,000
Closed -$841K – 8878
2021
Q3 		$841K Hold
50,000
– – ﹤0.01% 3604
2021
Q2 		$764K Sell
50,000
-34,900
-41% -$631K ﹤0.01% 3722
2021
Q1 		$1.65M Sell
84,900
-28,700
-25% -$609K ﹤0.01% 2672
2020
Q4 		$2.05M Sell
113,600
-28,500
-20% -$597K ﹤0.01% 2027
2020
Q3 		$2.74M Buy
142,100
+1,900
+1% +$43K 0.01% 1350
2020
Q2 		$3.66M Buy
140,200
+111,300
+385% +$2.72M 0.02% 1024
2020
Q1 		$516K Buy
28,900
+12,500
+76% +$338K ﹤0.01% 2030
2019
Q4 		$547K Buy
+16,400
New +$448K ﹤0.01% 2357
2019
Q1 		– Sell
-100
Closed -$4K – 5396
2018
Q4 		$4K Buy
+100
New +$4.5K ﹤0.01% 4536

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Group One Trading's URGN Position: Q1 2026 in Review

Group One Trading opened a new position in UroGen Pharma (URGN) in Q1 2026: 4,666 shares worth $83.9K. The stake represents ﹤0.01% of the portfolio and ranks #4884 among its holdings. This is a return to the name: Group One Trading previously reported a position in URGN as recently as Q1 2025.

Group One Trading first reported a position in URGN in Q3 2018 and has held it in 16 quarters since. The position peaked at $2.99M in Q3 2020. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Group One Trading held 4,666 shares of UroGen Pharma worth $83.9K as of Q1 2026.
  • UroGen Pharma was a new Group One Trading position in Q1 2026.
  • UroGen Pharma made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4884 holding.
  • Group One Trading first reported a position in UroGen Pharma in Q3 2018 and has held it in 16 quarters since.
  • Group One Trading's UroGen Pharma position peaked at $2.99M in Q3 2020.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.